ClinicalTrials.gg
RecruitingNCT06107010EarlyExoUpdated Feb 4, 2025

Effects of Atalante Exoskeleton on Gait Recovery in Non- or Poorly Ambulatory Patients with Hemiparesis in the Acute/subacute Phase (Month 1 to 4)

An interventional study of Use of the Atalante exoskeleton in Stroke, Acute, Stroke, Ischemic and Stroke, Subacute, sponsored by Wandercraft. Recruiting at 5 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-04.

Sponsored by Wandercraft · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 8 months ago, but the record still lists the study as recruiting.
  • Registered 4 months after the study started (first participant enrolled Jun 2023, registered Oct 2023).
  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 545 studies in Stroke with a site in France — 142 open to participants now, 161 under way, 12 of them phase 3. Stroke · France.

Planned enrollment
181st of 370
66 · median 64
Started
2023
with 29 others
No phase
277 of 545
93 open now
Primary completion
2026-02
later than 34 of 160 live
Registered
450th of 545
by date

Among the 545 studies in Stroke with a site in France, this one is the 181st largest by planned enrollment of the 370 interventional ones that give a count, is one of 30 that started in 2023, is one of 277 with no phase, reaches primary completion later than 34 of the 160 other live ones, and was the 450th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

142 of the 545 studies in Stroke with a site in France are open now. Recruiting first, the newest first:

137 more — sign in →

All 142 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 545 studies in Stroke with a site in France, or all of them as a file.
02

Study summary

The present clinical investigation - EarlyExo, is an interventional, international, multicentric, prospective, single-blinded randomized controlled trial.

This clinical investigation is designed to test the hypothesis that early and intense introduction of walking sessions assisted by the Atalante exoskeleton, in a sample of hemiparetic patients with still non or poor ambulatory capacities (FAC 0 or 1) between one- and four-months post stroke, would result in a better recovery of functional walking compared to a control group only receiving conventional therapy. Improved recovery will be measured through the proportion of patients reaching a FAC score of 4 or higher at the end of the intervention period. The tested hypothesis is that this proportion will be higher in the Exo group.

The duration of the intervention period in both groups is 6 weeks.

  • For the Exo group: 3 sessions per week (i.e., 18 one-hour sessions) with the Atalante device and 2 sessions per week (i.e., 12 one-hour sessions) of conventional therapy.
  • For the Control group: 5 sessions per week of conventional therapy (i.e., 30 one-hour sessions).

The study will include 66 patients (33 in each arm) and takes place in two French centers, two German centers and one Spanish center.

03

Conditions studied

  • Stroke, Acute
  • Stroke, Ischemic
  • Stroke, Subacute
  • Stroke Hemorrhagic
  • Cerebrovascular Disorders
  • Cerebrovascular Accident
  • Hemiparesis
  • Hemiparesis;Poststroke/CVA
  • Hemiparesis/Hemiplegia (One Sided Weakness/Paralysis)

Keywords

  • Robotics
  • Rehabilitation
  • Powered Exoskeleton
  • Walking recovery
  • Stroke
  • Acute stroke
  • Subacute stroke
  • Functional Ambulation Category
  • Randomized controlled study
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • >18 years old
  • First disability due to stroke
  • Hemiparesis in acute-subacute phase (1 to 4 months since lesion) due to a stroke
  • Functional Ambulation Category score (FAC) \<2
  • Patient with health insurance
  • Informed and willing to sign an form approved by the Ethics Committee. For clarity, if a motor impairment prevents the subject from signing by himself, he/she can still be included if the signature can be done by an impartial witness.

Exclusion criteria

Exclusion Criteria:

  • Muscle overactivity in hip adductors, hamstrings, quadriceps and plantar flexors, which interferes with exoskeleton use, based on clinician investigator's opinion
  • Recent fracture (\< 3 months) or any therapy inducing secondary osteoporosis
  • Excessive joint mechanical pain in the lower limbs based on clinician investigator's opinion
  • Pressure sore grade I or more over contact zones with Atalante system, according to the International Pressure Ulcer Classification System NPUAP - EPUA
  • Medical to medium intensity physical strain
  • Orthostatic hypotension (loss of > 20 mmHg systolic BP after 3 minutes in standing position)
  • Uncontrolled seizures
  • Morphological contra-indications to the use of Atalante (as per user's manual)
  • Pregnant woman
  • Adults who lack the capacity to provide , and all those persons deprived of their liberty in prisons or other places of detention
  • Concurrent participation in another interventional trial
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    Exo group

    During the 6-week intervention period, the Exo group will complete 3 sessions per week (i.e., 18 one-hour sessions) with the Atalante device and 2 sessions per week (i.e., 12 one-hour sessions) of conventional therapy. During sessions with the exoskeleton, the patient will perform ambulatory exercises with the device, with a gradual increase of intensity through the sessions. Conventional therapy corresponds to physiotherapy as part of post stroke standard of care of the center (tasks such as lower and upper limb practice, walking in parallel bars, etc., but this list is not exhaustive and depends on the practice of the therapists/centers).

    Device: Use of the Atalante exoskeleton

  • No intervention
    Control group

    During the 6-week intervention period, the Control group will complete 5 sessions per week of conventional therapy (i.e., 30 one-hour sessions).

Interventions

  • DeviceUse of the Atalante exoskeleton

    Six weeks of exoskeleton sessions replacing conventional therapy sessions three times a week

06

What researchers measure

Primary outcomes

  1. Walking recovery expressed by the proportion of patients reaching a Functional Ambulation Category (FAC) score of 4 or higher at the end of the intervention period, assessed without the exoskeleton.

    The FAC is a 6-item ordinal scale that classifies the level of support needed to walk safely, irrespective of the use of a lower extremity orthosis or walking aid, ranging from 0 (unable to walk without the assistance of two people) to 5 (independent walking on uneven surfaces and on stairs).

    Time frame: End of the intervention period (week 6)

Secondary outcomes

  1. Walking recovery expressed by the proportion of patients reaching a FAC score of 4 or higher at six months post stroke, assessed without the exoskeleton.

    Time frame: 6 months post stroke

  2. Time to reach FAC score of 4 or higher

    Time frame: Day 1 (± 3 days), week 2 (± 3 days) and week 4 (± 3 days) after the beginning of the intervention period, end of the intervention period (Week 6 ± 3 days), discharge from hospital and 6 months post stroke (± 6 days).

  3. Change in walking speed measured with the 10 Meter Walk Test (10MWT)

    The 10MWT is used to assess gait speed in meters/second over a short distance. Two tests are successively administered, barefoot, at comfortable then at maximal walking speed without walking aids. If a patient is unable to ambulate at all, a score of 0 m/s is documented.

    Time frame: Day 1 (± 3 days), end of the intervention period (Week 6 ± 3 days), discharge and 6 months post stroke (± 6 days)

  4. Changes in static and dynamic balance measured by the Berg Balance Scale (BBS)

    The BBS is a subjective, ordinal scale that assesses the ability to safely balance and avoid falls, during a series of functional tasks. It is thus also a measure of the amount of assistance needed to perform these tasks safely. In most items, the subject must maintain a given position for a specified time or complete moving tasks of varying difficulty. Subject receives a score from 0-4 at each of the 14 items on the ability to meet these balance dimensions.

    Time frame: Day 1 (± 3 days), end of the intervention period (Week 6 ± 3 days), discharge and 6 months post stroke (± 6 days)

  5. Change in transfer time from wheelchair to toilet and back to wheelchair

    The purpose is to record the time needed by the patient to do the transfer wheelchair /toilet seat/ wheelchair. Reduction of this time could mean an improvement of independence in daily life for stroke patients for whom transferring to the toilet is a common difficulty.

    Time frame: Day 1 (± 3 days), end of the intervention period (Week 6 ± 3 days), discharge and 6 months post stroke (± 6 days)

  6. Changes in maximal clinical muscle extensibility XV1 and maximal range of active motion XA against the resistance of the key lower limb muscles using the Five Step Assessment

    Measurements of XV1 and XA for soleus, gastrocnemius, gluteus maximus, hamstrings, vastus and rectus femoris muscles, using to the Five Step Assessment * XV1 is the angle of arrest at slow speed of stretch, corresponding to the passive range of motion against the resistance of the tested muscle. * XA is the maximal active range of motion against the resistance of the evaluated antagonist muscle.

    Time frame: Day 1 (± 3 days), end of the intervention period (Week 6 ± 3 days), discharge and 6 months post stroke (± 6 days)

  7. Changes in anxiety and depression scores using the Hospital and Depression scale (HAD)

    The HAD is a two-dimension self-administered questionnaire developed to identify depression and anxiety among physically ill patients. Identifying these disorders and the context in which they develop is interesting as motivation of the patient seems to have an important impact on his progression. It consists of 14 items rated with a score from 0-4, divided into 7 items for anxiety and 7 items for depression based on the concept of anhedonia.

    Time frame: Day 1 (± 3 days), end of the intervention period (Week 6 ± 3 days), discharge and 6 months post stroke (± 6 days)

  8. Changes in perceived quality of life assessed by the Short Form-36 (SF-36)

    The SF-36 is a self-administered questionnaire that provides an evaluation of the generic Quality of Life. The version used is the RAND-36 Item Health Survey. There are 36 items (or questions) divided into eight domains: Physical component: 1. Physical functioning 2. Role limitations due to physical problems 3. Bodily pain 4. General health perceptions Mental component: 5. Social functioning 6. General mental health 7. Role limitations due to emotional problems 8. Vitality Each item is answered by the subject with a Likert scale.

    Time frame: Day 1 (± 3 days) and 6 months post stroke (± 6 days)

  9. Subject and Therapist satisfaction and willingness to continue training sessions

    The subject is asked to answer two questions regarding his satisfaction and willingness to continue training sessions. The therapist answers one question on his satisfaction. The score of each question is evaluated with a 5-level Likert scale.

    Time frame: End of Week 1 (± 3 days), end of Week 3 (± 3 days) and end of the intervention period (Week 6 ± 3 days)

  10. Perceived workload by the therapists conducting sessions assessed with the NASA Task Load Index

    The NASA Task Load Index is a multidimensional, subjective scale that rates perceived workload in order to assess a task.There are six items, answered by the therapists after the therapy session: 1. Mental demand 2. Physical demand 3. Temporal demand 4. Effort 5. Performance 6. Frustration level The therapist gives his answers for the task "conducting a therapy session with the Atalante device" for patients of the Exo group, and for the task "conducting a conventional therapy session" for patients of the Control group.

    Time frame: End of Week 1 (± 3 days) and end of the intervention period (Week 6 ± 3 days)

07

Study locations

4 of 5 sites recruiting
  • Hôpitaux Universitaires Henri Mondor APHP, site Albert Chenevier
    Créteil, France
    Recruiting
  • Centre de Médecine Physique et de Réadaptation APAJH de Pionsat
    Pionsat, France
    Recruiting
  • Schön Klinik
    Bad Aibling, Germany
    Not yet recruiting
    • Dr Friedemann Müller, MD, M.Sc. · Contactfmueller@schoen-klinik.de
    • Dr Friedemann Müller, MD, M.Sc. · Contact
    • Pr Klaus Jahn, MD · Contact
  • Vivantes Klinikum Spandau
    Berlin, Germany
    Recruiting
    • Dr Anatol Kivi, MD · Contactanatol.kivi@vivantes.de
    • Dr Anatol Kivi, MD · Contact
    • Pr Jörg Wissel, MD · Contact
  • Institut Guttmann
    Barcelona, Spain
    Recruiting
    • Dr Cristian Andres Figueroa Chacón, MD · Contactcafigueroa@guttmann.com
    • Dr Cristian Andres Figueroa Chacón, MD · Contact
    • Dr Irene Sanchez Serrano, MD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Feb 2026, 32 months after the start.

Of 144 industry-sponsored interventional studies with no phase under Stroke, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's planned 32 months is above that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2023
First posted
Oct 30, 2023
StartActual
Jun 12, 2023
Primary completionEst.
Feb 28, 2026
CompletionEst.
Feb 28, 2026
Last update
Feb 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06107010
Lead sponsor
Wandercraft
Responsible party
Sponsor
First posted
Oct 30, 2023
Start date
Jun 12, 2023
Primary completion
Feb 28, 2026 (estimated)
Completion
Feb 28, 2026 (estimated)
Last update
Feb 4, 2025

Study contacts

Dr Rebecca Sauvagnac, MD
Contact
rebecca.sauvagnac@wandercraft.health
(0)179353109
Laure Bouché
Contact
laure.bouche@wandercraft.health
(0)179353109

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion